PACS Group, Inc.
No enriched coverage for $PACS in the last 7 days.
Murray Jason Hulse (Co-Founder, CEO & Chairman) sold 19,617 shares of PACS Group, Inc. (PACS) at an average of $45.19 ($45.03–$45.23, $0.89M total) across 3 trades over 2026-09-10 to 2026-09-14 under a Rule 10b5-1 trading plan.
Murray Jason Hulse (Co-Founder, CEO & Chairman) sold 51,887 shares of PACS Group, Inc. (PACS) at an average of $43.12 ($42.68–$43.59, $2.24M total) across 5 trades over 2026-09-04 to 2026-09-09 under a Rule 10b5-1 trading plan.
Murray Jason Hulse (Co-Founder, CEO & Chairman) sold 68,113 shares of PACS Group, Inc. (PACS) at an average of $42.63 ($42.35–$43.36, $2.90M total) across 6 trades over 2026-09-01 to 2026-09-03 under a Rule 10b5-1 trading plan.
Recent PACS coverage spans insider activity, mergers & acquisitions and financial news.
In the last 30 days, PACS insiders filed 23 SEC Form 4 transactions — no purchases and 23 sales ($23.1M). The most active reporter was Murray Jason Hulse, Co-Founder, CEO & Chairman, with 23 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale is modest relative to total holdings and likely exerts slight downward pressure on the stock.
The insider sale may signal confidence concerns, but the size is modest relative to total shares outstanding.
Insider sale by the founder/CEO may signal limited confidence in near‑term upside.
The acquisitions increase PACS' market footprint and leverage low net debt, likely supporting further share price upside.
The acquisitions increase PACS' footprint and bed count, likely supporting revenue growth.
AlphAI scores every news story that mentions PACS with an AI model for sentiment and relevance, and aggregates insider trades from PACS Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Murray Jason Hulse (Co-Founder, CEO & Chairman) sold 19,617 shares of PACS Group, Inc. (PACS) at an average of $45.19 ($45.03–$45.23, $0.89M total) across 3 trades over 2026-09-10 to 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readMurray Jason Hulse (Co-Founder, CEO & Chairman) sold 51,887 shares of PACS Group, Inc. (PACS) at an average of $43.12 ($42.68–$43.59, $2.24M total) across 5 trades over 2026-09-04 to 2026-09-09 under a Rule 10b5-1 trading plan.
1 min readMurray Jason Hulse (Co-Founder, CEO & Chairman) sold 68,113 shares of PACS Group, Inc. (PACS) at an average of $42.63 ($42.35–$43.36, $2.90M total) across 6 trades over 2026-09-01 to 2026-09-03 under a Rule 10b5-1 trading plan.
1 min readPACS stock rose 3.3% premarket after announcing two growth initiatives: acquiring 32 Florida nursing facilities and closing 11 more from the Eduro Healthcare deal, expanding its network to 355 buildings. The company's stock has recovered from a 52-week low of $7.50, now trading at $43.52. PACS's low leverage and favorable Medicare reimbursements support its growth strategy.
2 min readPACS Group (NYSE:PACS) shares rose 3.3% premarket after announcing plans to acquire 32 Florida skilled nursing facilities, adding 4,049 beds. The deal, expected to close Q4, expands PACS's southern footprint. Additionally, PACS completed closings on 11 more Eduro Healthcare facilities, bringing total Eduro closings to 31 of 34. The company now operates 355 facilities across 7 states. CEO Jason Murray highlighted Florida's growth potential.
2 min readConway Patrick Hugh sold 3,497 shares of PACS Group, Inc. (PACS) at $44.41 ($0.16M total) on 2026-08-14.
1 min readMurray Jason Hulse (Co-Founder, CEO & Chairman) sold 150,550 shares of PACS Group, Inc. (PACS) at an average of $43.92 ($43.61–$44.76, $6.61M total) across 4 trades over 2026-08-20 to 2026-08-21 under a Rule 10b5-1 trading plan.
1 min readOn Wednesday, notable insider trading activity occurred in U.S. stocks. Zentalis Pharmaceuticals (ZLAB) saw a major purchase by Walters Group, while Bakkt (BKKT), Universal Safety Products (UNSP), Advanced Flower Capital (AFCG), and Brilliant Earth (BID) also had significant insider buys. Astera Labs (ALAB), Adaptive Biotechnologies (ADPT), and PACS Group (PACS) reported insider sales, some mandatory for tax purposes. InvestingPro analysis suggests some stocks are undervalued or overvalued.
3 min readMurray Jason Hulse (Co-Founder, CEO & Chairman) sold 236,116 shares of PACS Group, Inc. (PACS) at an average of $44.20 ($43.34–$44.85, $10.44M total) across 5 trades over 2026-08-17 to 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readJergensen Joshua (President & COO) sold 40,000 shares of PACS Group, Inc. (PACS) at an average of $45.59 ($44.53–$45.70, $1.82M total) across 2 trades on 2026-08-12 under a Rule 10b5-1 trading plan.
2 min read